ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RPRX vs GMAB // GROSS PROFIT MARGIN

Royalty Pharma plc (Class A) (NASDAQ) VS. Genmab A/S ADS (NASDAQ) • 15-METRIC TALLY: RPRX 4 — GMAB 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RPRX VS. GMAB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RPRX GMAB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 7.00% 9.90% -2.90 GMAB /roic <GO>
EV/EBITDA & P/E Valuation 27.8x 21.0x +6.80 GMAB /valuation <GO>
Free Cash Flow Yield 6.29% 2.21% +4.08 RPRX /fcf-yield <GO>
Operating Margin 65.60% 13.90% +51.70 RPRX /operating-margins <GO>
Net Profit Margin 32.40% 10.90% +21.50 RPRX /net-margins <GO>
Revenue Growth (YoY) 5.10% 22.00% -16.90 GMAB /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.90 3.74 -0.84 GMAB /balance-sheet <GO>
Piotroski F-Score Quality 8/9 8/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 68.6 85.2 -16.60 GMAB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.94 1.09 -0.15 GMAB /macro-sensitivity <GO>
Forward P/E Multiple 45.8x 27.6x +18.20 GMAB /forward-pe <GO>
Enterprise Scale & Market Cap $37.91B $35.25B $2.66B RPRX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RPRX REV GMAB REV RPRX GROSS % GMAB GROSS % RPRX FCF GMAB FCF
FY 2025 $2.38B — — — $2.38B —
FY 2024 $2.26B — — — $2.67B —
FY 2023 $2.35B — — — $2.88B —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RPRX // BETA 0.94
GMAB // BETA 1.09